Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05190653 |
| Early Integration of Palliative and Supportive Care in Cellular Therapy(PALS_CT) |
| unknown |
| N/A |
| 152 |
| Alberta Health Services, CalgaryOTHER |
| 1 |
| Jul 31, 2024 |
| clinicaltrials |
| NCT06445257 | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL | unknown | N/A | 30 | Huai'an First People's HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06379282 | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia(HIT-CLL) | unknown | N/A | 132 | University of SurreyOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05536154 | Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies | unknown | N/A | 68 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05697913 | Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation | unknown | N/A | 66 | Hospital Galdakao-UsansoloOTHER_GOV | 0 | Mar 6, 2024 | clinicaltrials |
| NCT05284825 | A Phase II Trial of Intermediate Radiation Dose For Lymphoma | unknown | N/A | 27 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06258096 | LI-TASTE Study: Light for Taste(LI-TASTE) | unknown | N/A | 52 | Academic Centre for Dentistry in AmsterdamOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT06203145 | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM | unknown | N/A | 30 | Peking University First HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05308875 | Efficacy and Safety Evaluation of PD1-BCMA-CART | unknown | N/A | 9 | Bioray LaboratoriesINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06160362 | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 7, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03121456 | 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma(LYMPHODTECT) | unknown | N/A | 74 | Centre Antoine LacassagneOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05378971 | Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma | unknown | N/A | 15 | LanZhou UniversityOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT06060080 | Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma | unknown | N/A | 7 | Yao LiuOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05995808 | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests | unknown | N/A | 30 | Sohag UniversityOTHER | 0 | Aug 16, 2023 | clinicaltrials |
| NCT05376709 | A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population | unknown | N/A | 200 | National Taiwan University HospitalOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05964270 | Telemonitoring Among Patients With Multiple Myeloma(ITUMM) | unknown | N/A | 150 | IsalaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05893693 | Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 12 | Aibin Liang,MD,Ph.D.OTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05822037 | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05797948 | GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | unknown | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05548686 | Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple Myeloma(ALGOMYELOMOV) | unknown | N/A | 15 | University Hospital, CaenOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05448404 | A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma | unknown | N/A | 30 | First Hospital of China Medical UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | N/A | 1 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05381077 | Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner(MM-ZTE) | unknown | N/A | 30 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | unknown | N/A | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT03574454 | Machine Learning in Myeloma Response(MALIMAR) | unknown | N/A | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05184595 | Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib(ADHOMY2) | unknown | N/A | 52 | Central Hospital, Nancy, FranceOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | unknown | N/A | 23 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05088330 | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | unknown | N/A | 76 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Oct 21, 2021 | clinicaltrials |
| NCT04320420 | Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²)(APA²) | unknown | N/A | 57 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05024357 | A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | unknown | N/A | 80 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05026229 | A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05059847 | Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults | unknown | N/A | 114 | Hospital General de MexicoOTHER_GOV | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04862806 | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | unknown | N/A | 1,000 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 17, 2021 | clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04370457 | MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies | unknown | N/A | 300 | Centre for Research and Technology HellasOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04914143 | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy | unknown | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04792593 | Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | N/A | 15 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04665076 | Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors | unknown | N/A | 60 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT03380039 | Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma | unknown | N/A | 6 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04447573 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 29, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2025source: clinicaltrials